June 06, 2014
A Missouri federal judge on Friday dismissed K-V Pharmaceutical Co. investors' consolidated securities fraud class action accusing the company of lying about prospects for pregnancy drug Makena, artificially inflating the stock price that later plummeted, and refused their proposals to amend it.
October 20, 2011
A K-V Pharmaceutical Co. shareholder filed a putative class action in Missouri on Wednesday claiming the drugmaker lied to investors about prospects for pregnancy drug Makena, artificially inflating the stock price that later plummeted when demand for the drug fizzled.